Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Itraconazole on Ganaplacide and Lumefantrine PK
NCT05084651Phase 1Completed
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ganaplacide and lumefantrine in malaria, sponsored by Novartis. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Quantifiable Concentration and 5 more. Started Nov 2021; status: completed.
02
Drugs
ganaplacidelumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05084651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084651.